INDBInternet News Database 2.5 Updated just now · 288 sources Show or hide images Light or dark

Results for “Novo Nordisk”

1 source

Who is covering this

ReutersCenter
Truth score 47
Centre 100%100%
ReutersCenter

Novo Nordisk's Wegovy pill beats forecasts as it battles Lilly

Novo Nordisk's Wegovy pill beats forecasts as it battles Lilly Reuters

Lean: Center Fact-focusedFactuality: Very highCountry: United KingdomFunding: CorporateOwner: Thomson Reuters
Full coverage
Coverage breakdown
Funding
Corporate100%
Countries
United Kingdom100%
Media ownership
Thomson Reuters100%
Avg reliability92
Low-credibility share0%
Fact / opinion1/0
State media0%
More analysis
Truth score: 47 (Limited corroboration) Propaganda risk: 0 Trending: Low Sources: 1 Reliability: 92 Bias severity: 0 Risk: 0Sentiment: 0Sensationalism: 0 Amplification: 0

How we score

Analyze: Coverage Heat Map
Like
World
1 source

Who is covering this

The Epoch TimesRight
Truth score 17Factuality: Low
Right 100%100%
The Epoch TimesRight

First Weight-Loss Tablet Approved for Use in Australia

Low reliability sourceElevated risk

A sign bearing the logo of Novo Nordisk next to the company's factory in Hillerod, Denmark, on Nov. 12, 2025. (Sergei Gapon/AFP via Getty Images)

Lean: Right Fact-focusedFactuality: LowCountry: United StatesFunding: PrivateOwner: Epoch Media Group
Full coverage
Coverage breakdown
Funding
Private100%
Countries
United States100%
Media ownership
Epoch Media Group100%
Avg reliability35
Low-credibility share100%
Fact / opinion1/0
State media0%
More analysis
Truth score: 17 (Weakly supported) Propaganda risk: 0 Trending: Low Sources: 1 Reliability: 35 Bias severity: 0 Risk: 100Sentiment: 0Sensationalism: 0 Amplification: 0

How we score

Analyze: Coverage Heat Map
Like
1 source

Who is covering this

CNBCCenter
Truth score 43
Centre 100%100%
CNBCCenter

Novo raises full-year outlook as Wegovy pill sales impress

Novo posted quarterly earnings ahead of expectations early Wednesday as sales of its Wegovy pill blew past estimates

Lean: Center Fact-focusedFactuality: HighCountry: United StatesFunding: Corporate
Full coverage
Coverage breakdown
Funding
Corporate100%
Countries
United States100%
Media ownership
CNBC100%
Avg reliability80
Low-credibility share0%
Fact / opinion1/0
State media0%
More analysis
Truth score: 43 (Limited corroboration) Propaganda risk: 0 Trending: Low Sources: 1 Reliability: 80 Bias severity: 0 Risk: 0Sentiment: 0Sensationalism: 0 Amplification: 0

How we score

Analyze: Story Timeline
Like
Health
1 source

Who is covering this

MedpagetodayCenter
Truth score 38
Centre 100%100%
MedpagetodayCenter

Study Strengthens Case for Stent-Free PCI in De Novo Coronary Lesions

(MedPage Today) -- For de novo coronary lesions, drug-coated balloons (DCBs) were just as effective as standard drug-eluting stents, the TRANSFORM II trial showed. Among patients with native coronary lesions undergoing percutaneous...

Lean: Center Fact-focusedFactuality: Mostly factualCountry: United StatesFunding: CorporateOwner: Independent
Full coverage
Coverage breakdown
Funding
Corporate100%
Countries
United States100%
Media ownership
Independent100%
Avg reliability65
Low-credibility share0%
Fact / opinion1/0
State media0%
More analysis
Truth score: 38 (Weakly supported) Propaganda risk: 0 Trending: Low Sources: 1 Reliability: 65 Bias severity: 0 Risk: 0Sentiment: 0Sensationalism: 0 Amplification: 0

How we score

Analyze: Misinfo Radar
Like